The Setup

Molina Healthcare (MOH) detonated yesterday. Guided 2026 EPS to $5.00 vs $13.71 consensus — a 63% miss, worst MCO guidance disaster in recent memory. Stock cratered -33% after hours, closed today -25.5% at $131.72.

The contagion hit everyone. Centene (CNC) dropped -10.6% post-market despite beating estimates and guiding above consensus. That's the trade: forced selling on a name that did exactly what it was supposed to do.

CNC actual numbers (Feb 6, 2026 8-K):

  • Q4 2025 adj EPS: -$1.19 vs -$1.22 est ✓ (beat by $0.03)
  • Q4 revenue: $49.7B vs $48.4B est ✓ (beat by $1.3B)
  • 2026 EPS guidance: >$3.00 vs $2.88 consensus ✓ (guide above by $0.12+)

Price action:

  • Pre-earnings: $43.09
  • Post-market (Feb 6): $35.69 (-17.2%)
  • Today close: $38.46 (-10.8% from pre-earnings)
  • RSI: 23 (deeply oversold)
  • Forward P/E: 9.5x on management's self-described "trough year" EPS

This is contagion selling on a company that guided UP, not down.

What CNC Actually Has

The Q4 transcript reveals a specific, measurable cost lever that smaller MCOs can't replicate.

1. ABA Behavioral Health Crackdown (Differentiated)

The problem: ≈50% of Medicaid excess trend is behavioral health, specifically Applied Behavioral Analysis (ABA) therapy for kids.

What CNC found: Leveraged 29-state data footprint to identify systematic outlier patterns:

  • Kids enrolled in therapy 5-10 years vs clinical optimum of 2-3 years
  • 40 hours/week enrollments vs balanced school-integrated care
  • Lack of board-certified behavioral analyst oversight

The action:

  • Launched ABA-specific engagement programs
  • Directly engaging states on program reform
  • Scoring 75 algorithms on claims data for fraud detection

Proof points in the numbers:

  • Q2 2025 Medicaid HBR: 94.9%
  • Q3 2025: 93.4% (-150 bps)
  • Q4 2025: 93.0% (-40 bps sequential)
  • 2026 guidance: 93.7% (flat, potentially conservative if ABA lever continues)

This isn't "we're managing costs better" generic commentary. This is a data-driven intervention targeting the largest single driver of excess Medicaid trend, with sequential improvement already showing.

Scale matters: CNC's 29-state data set enables pattern detection that smaller plans simply can't match. You need volume to see the outliers.

2. No Surprises Act Headwind (Real Cost)

The counterweight. NSA is getting "increasingly weaponized by market participants" via the IDR (independent dispute resolution) process. CNC filed a multimillion-dollar lawsuit against a NY provider for "fraudulent manipulation of in-network/out-of-network claims."

Q4 impact: NSA disputes drove ~100 bps unexpected HBR in Marketplace segment (out-of-period items pushed Marketplace HBR from baseline expectations).

2026 outlook: CNC accrued additional NSA costs for 2025 dates of service AND factored into 2026 guidance. At 5.5M Marketplace members (largest individual market insurer), this is a meaningful drag.

Management taking "more proactive litigious posture," but this requires legislative reform or successful litigation to control — operational levers are limited.

3. EAPTC Subsidy Cliff (Known Risk)

Post-EAPTC expiration, Bronze plan enrollment surged to 30%+ of Marketplace mix (vs 19-24% historical). Structural shift as subsidy-dependent members move to cheapest options.

Membership impact:

  • Dec 2025: 5.0M Marketplace members
  • Expected Q1 2026 ending: 3.5M (-30%)

CNC says paid membership rates "in line with expectations" and January tracking to plan. They reduced footprint where they were "low-cost bronze player." Commissioned Wakely actuarial report on market-wide paid/metallic distribution to improve risk adjustment.

This is a known risk, already in guidance. Not a surprise.

4. Competitive Consolidation (Opportunity)

CEO Sarah London explicitly noted smaller nonprofit Medicaid plans are struggling under rate pressure, creating "potential membership growth" opportunity as competitors exit geographies.

Combined with CNC's 29-state scale advantage in medical cost management (ABA analytics, fraud detection), CNC is positioned to consolidate Medicaid market share as weaker players exit.

Counter-narrative: Simple "Medicaid = headwind" thesis misses that distress creates concentration opportunity for survivors with operational scale.

The Sector Context

Every major MCO is calling 2026 the trough:

  • ELV (Elevance): Medicaid margin guidance ~-1.75%, "trough year," rate increases lag trend
  • MOH (Molina): "Imbalance between rates and trend marks 2026 as a trough year for Medicaid industry margins"
  • CNC (Centene): >$3 EPS on 93.7% Medicaid HBR, management calling it recovery playbook

Cross-ticker signal from INNV (Innova Medical):

  • Q2 FY2026: Operating income $13.3M vs ($12.6M) loss YoY
  • Revenue +15% YoY driven by 8% Medicaid rate increases + 4.1% Medicare increases

If states are starting to restore rates (INNV seeing 8% in their footprint), and CNC has a specific cost lever (ABA) already compressing HBRs sequentially, the >$3 EPS guidance could be sandbagged.

What This Isn't

NOT trade-ready. No alpha calculation, no target price, no segment EPS bridge, no EAPTC sensitivity analysis, no factor decomposition vs MCO peers.

Risks the market is screaming about:

  1. "Trough year" could be wrong — MOH just proved these guides can crater further
  2. EAPTC membership loss is massive (-30% Marketplace) and adverse selection risk is real
  3. NSA headwind is quantifiable (≈$400M+ annualized) and worsening
  4. ABA lever is management commentary — not independently verified, could be optimistic
  5. Rate restoration is an assumption — if states don't deliver, margins stay compressed

Why Escalate

Valuation dislocation on contagion selling.

CNC beat estimates, guided above consensus, and trades at 9.5x forward P/E on self-described trough earnings at RSI 23 because Molina imploded.

The combination of:

  • Forced selling (down 10%+ on a beat-and-raise)
  • Deeply oversold technicals (RSI 23, -34% 1Y, 33% of 52-week range)
  • Specific cost lever showing results (sequential Medicaid HBR improvement 94.9→93.4→93.0)
  • Sector calling synchronized trough (if rate restoration materializes, CNC has operational leverage via ABA + competitive consolidation)

...creates a setup worth proper alpha work before the window closes.

What's needed:

  • Target price with segment-level EPS bridge
  • EAPTC sensitivity (membership loss impact vs Bronze mix margin offset)
  • Benchmark factor decomposition (CNC vs ELV/MOH/HUM — is this idiosyncratic or pure sector beta?)
  • Independent verification of ABA cost lever magnitude
  • State-by-state Medicaid rate advocacy tracker (where is rate restoration actually happening?)

The opportunity: If the entire MCO sector is calling 2026 the trough, and CNC has the most operational leverage (ABA lever + scale advantage in competitive consolidation), this is the kind of dislocation where magnitude edge exists even if discovery edge doesn't.

Market knows the thesis. Question is whether they're underestimating the size of the recovery when rates restore and ABA costs compress further.